QUEST informs readers of the latest advances in urologic prostate cancer research, especially detection, prevention, and treatment.
“I do not believe the robotic prostatectomy is as safe a cancer operation as open radical prostatectomy.” In my opinion, the robotic prostatectomy (often called the DaVinci prostatectomy) is not as effective as the traditional open prostatectomy for accomplishing sometimes…
(This article is based upon research information published in Nature Genetics, June 2006. Dr. Catalona is one of the co-authors and his research population from the Northwestern prostate SPORE Pathology Core is one of the US groups studied. This material…
Before Marty Koch was diagnosed with prostate cancer, at the age of 49, he had never needed stitches for anything – much less been in a hospital. Needless to say, he was scared. Koch described himself as “being on the…
Differing comments are in the media regarding the use of PSA tests. In this article, Dr. Catalona, whose research developed the use of PSA tests for the early detection of prostate cancer, presents his personal and most recent recommendations for…
Dr. Catalona is presenting the case for early detection of prostate cancer at medical conferences across the United States. QUEST is including information from his presentation in this issue and in upcoming issues.
No way to know for certain that any tumor is insignificant Some academic centers are moving toward not immediately treating prostate cancer patients who have favorable tumor features (i.e., low Gleason grade and low volume of cancer in biopsy specimens),…
(Dr. Catalona received the 2005 Huggins Award from the Society of Urologic Oncology and gave the Award Lecture on The PSA Dilemma in the Overdiagnosis and Underdiagnosis of Prostate Cancer. This article in QUEST is a summary of that lecture…
A Univeral Approach My prior article in QUEST, Winter 2005, described a “universal” approach to achieving a high likelihood of long-term remission and a return to a positive life for a wide range of prostate cancer patients who have low-risk…
To facilitate prostate cancer gene mapping and identification, the ICPCG was established in 2002 Dr. Catalona will be a co-investigator for a prostate cancer susceptibility study sponsored by ICPCG, the International Consortium for Prostate Cancer Genetics. (William Isaacs, PhD, Johns…
Dr. Catalona has built upon his findings to discover various components of PSA One of the most serious dilemmas in diagnosing prostate cancer is that the PSA test, recognized first by Dr. Catalona as an invaluable tool for early detection…
"*" indicates required fields
